This program is supported by an independent education grant from Pfizer. This online education program has been designed solely for healthcare professionals in the US. The content is not available for healthcare professionals in any other country.

In this virtual webinar, leading experts Dr Seth Wander, Dr Mark Pegram and Jamie Carroll deliver a 45-minute live, expert-led virtual roundtable designed to improve healthcare professional performance in optimizing and sustaining first-line maintenance strategies in HER2+ metastatic breast cancer (MBC). Delivered in an interactive tumor board-style format featuring a community oncologist and an oncology nurse practitioner, this session simulates real-world multidisciplinary decision-making across complex, evolving patient cases.

Participants will evaluate patient- and disease-specific factors to personalize first-line maintenance strategies, including endocrine integration and optimal treatment sequencing in HER2+/HR+ MBC.

Credits: 0.75 AMA PRA Category 1 Credits™ (0.75.00 hours)

Session Highlights

• Personalized 1L Maintenance: Evaluate patient- and disease-specific factors to tailor first-line maintenance plans and integrate endocrine therapy in HER2+/HR+ MBC.
• Evidence-Driven Decisions: Translate recent clinical data into actionable treatment selection, sequencing, and transition strategies for routine practice.
• Proactive Toxicity Management: Implement multidisciplinary care strategies to effectively manage treatment toxicities and support therapeutic continuity.
• Simulated MDT Collaboration: Participate in real-time tumor board decision-making and interactive Q&A with a community oncologist and oncology nurse practitioner.

Who Should Watch

This program is designed for HCPs in community and academic settings directly responsible for 1L treatment decision-making, therapy selection and sequencing, and ongoing management of patients with HER2+ MBC:

Specialty

• Medical oncologists
• Oncology nurses
• Nurse practitioners (oncology-focused)
• Physician assistants (oncology-focused)
• Pharmacists (oncology-focused)

Presented by

Dr. Seth Wander, MD, PhD, is a medical oncologist at Massachusetts General Hospital (MGH), Director of Translational Research for the Breast Oncology Program, Director of Precision Medicine in the Termeer Center for Targeted Therapies, and an Assistant Professor of Medicine at Harvard Medical School. He earned his undergraduate degree from Cornell University before completing his MD/PhD in Cancer Biology at the University of Miami, internal medicine residency at MGH, and a medical oncology fellowship at Dana-Farber Cancer Institute and MGH Cancer Center. Dr. Wander’s clinical and translational research focuses on breast cancer genomics and precision oncology, leveraging advanced molecular sequencing to decode mechanisms of drug resistance and design novel, personalized clinical trials. An active trialist across all phases of drug development with over 70 peer-reviewed publications, his work has earned recognitions including the ASCO Young Investigator Award and the Dana-Farber Wong Family Translational Research Award.

Dr. Mark Pegram, MD, is the Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology, Associate Dean for Clinical Research Quality at the Stanford University School of Medicine, Associate Director of Clinical Research at the Stanford Comprehensive Cancer Institute (SCCI), and Medical Director of the Stanford Clinical Translational Research Unit. He earned his medical degree from the University of North Carolina at Chapel Hill, completed his residency at the University of Texas Southwestern Medical Center, and completed fellowship training at the UCLA David Geffen School of Medicine. Dr. Pegram’s research focuses on the HER2 oncogene, the development of targeted therapies for HER2-positive metastatic breast cancer, and the clinical implementation of oncology biosimilars. Author of over 110 peer-reviewed publications, he leads extensive translational research and early-phase, first-in-human clinical trials.

Jamie Carroll APRN, C.N.P M.S.N is a nurse practitioner with a Women’s Health Care Nurse Practitioner certification, currently working for Mayo Clinic in Breast Cancer since July 2015. She holds a master’s degree from the University of Nebraska Medical Center, graduating in 2012. Her clinical interests are in quality improvement within the breast cancer teams, ensuring under-represented individuals have access to quality health care, promoting equity and an inclusive and supportive environment for all patients. She is involved in the RAINBOWS clinic at Mayo which is an affirming clinic for LGBTQ+ patients with breast cancer. Jamie also strives to improve survivorship for breast cancer patients. Jamie enjoys education of students, nurses and fellow colleagues across the nation. She has earned the status of Assistant Professor through Mayo Clinic College of Medicine and Science.

Continuing Education Information

Commercial support: This activity received monetary support through an independent education grant from Pfizer.

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Disclosures

Seth Wander, MD has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Consulting or Advisory Role: Arvinas, AstraZeneca, Biovica, Boundless Bio, Celcuity, Foundation Medicine, Genentech/Roche, Gilead Sciences, Halda Therapeutics, Hologic, Lilly, Novartis, Pfizer, Precede Bio, Puma Biotechnology, Regor Therapeutics, Stemline Therapeutics, Veracyte Speakers’ Bureau: 2nd. MD, Guardant Health, Lilly Research Funding: Arvinas, Genentech, Lilly, Nuvation Bio, Pfizer, Phoenix Molecular Designs, Puma Biotechnology, Regor Therapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics

Dr. Mark Pegram, MD has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Honoraria: Novartis, Stemline Therapeutics, AstraZeneca; Consulting or Advisory Role: Genentech/Roche, Pfizer, Gilead Sciences, Tersera

Jamie Carroll APRN, C.N.P., M.S.N has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Consulting or Advisory Role: AstraZeneca, Eli Lilly, Novartis.

AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible companies. All relevant financial relationships for anyone associated with the content of this activity were mitigated prior to the release of this program.

Activity Accreditation for Health Professions

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

System Requirements

Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

• When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
• Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.

Participation Costs

There is no cost to participate in this program.

This continuing education activity is active starting November 5th 2026 and will expire on November 5th 2026. Estimated time to complete this activity: 45 minutes.